Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cimetidine
Drug ID BADD_D00467
Description A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Indications and Usage For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
Marketing Status Prescription; OTC; Discontinued
ATC Code A02BA01
DrugBank ID DB00501
KEGG ID D00295
MeSH ID D002927
PubChem ID 2756
TTD Drug ID D02DPA
NDC Product Code 63029-222; 0378-0317; 0093-8192; 0378-0372; 42291-218; 49452-2063; 62991-1456; 70934-931; 30142-323; 71052-456; 63629-1783; 53002-3280; 0093-8204; 0395-8079; 42291-217; 49035-820; 50090-3574; 70518-2809; 0363-0022; 0093-8305; 0378-0541; 38779-0325; 55289-581; 49964-0006; 51552-0531; 59779-022; 69256-022; 49711-0095; 51927-2750; 63629-1497; 63187-333; 49348-246; 0378-0053; 50090-0500; 72288-022; 24385-111; 51927-0190; 0113-0022
Synonyms Cimetidine | N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine | Biomet | Biomet400 | Cimetidine Hydrochloride | Hydrochloride, Cimetidine | Cimetidine HCl | HCl, Cimetidine | Histodil | SK&F-92334 | SK&F 92334 | SK&F92334 | SKF-92334 | SKF 92334 | SKF92334 | Tagamet | Altramet | Eureceptor
Chemical Information
Molecular Formula C10H16N6S
CAS Registry Number 51481-61-9
SMILES CC1=C(N=CN1)CSCCNC(=NC)NC#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Haemolytic anaemiaUDP-glucuronosyltransferase 1A1P22309T934809059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
Haemolytic anaemiaL-lactate dehydrogenase B chainP07195Not Available9059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
Hyperparathyroidism secondaryParathyroid hormoneP01270T987086689302; 6547988; 6090499
Hyperparathyroidism secondaryCalcineurin subunit B type 1P63098Not Available6689302; 6547988; 6090499
ThrombocytopeniaBifunctional epoxide hydrolase 2P34913T357348326296; 3966212; 3614578; 9101005
ThrombocytopeniaL-lactate dehydrogenase C chainP07864Not Available9059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Piloerection23.02.06.0050.008597%Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polymyositis15.05.01.004; 10.04.05.004--Not Available
Pyrexia08.05.02.0030.008597%
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Restlessness19.11.02.002; 17.02.05.0210.008597%
Sinus bradycardia02.03.03.009--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Strongyloidiasis07.19.02.006; 11.08.01.002--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.011462%
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Torsade de pointes02.03.04.0050.017193%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.001495%
Type I hypersensitivity10.01.03.0060.008597%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.008597%
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.0010.017193%
Ventricular tachycardia02.03.04.0100.037252%
Vomiting07.01.07.0030.014328%
White blood cell count decreased13.01.06.012--
Tubulointerstitial nephritis20.05.02.002--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.015--Not Available
Mental disorder due to a general medical condition19.07.03.005--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages